| 前收市價 | 12.75 |
| 開市 | 13.00 |
| 買盤 | 14.89 x 200 |
| 賣出價 | 14.95 x 700 |
| 今日波幅 | 12.86 - 14.94 |
| 52 週波幅 | 8.79 - 32.10 |
| 成交量 | |
| 平均成交量 | 2,074,254 |
| 市值 | 715.805M |
| Beta 值 (5 年，每月) | -0.57 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.17 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2012年12月13日 |
| 1 年預測目標價 | 103.00 |
Motley FoolWhy Cassava Sciences Stock Is Skyrocketing Today
Investors liked what Cassava's new executive chairman had to say.
ZacksBiotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
BenzingaCassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's Trials
Cassava Sciences Inc (NASDAQ:SAVA) stock is trading lower on Wednesday on a heavy session volume of 14.35 million, as per data from Benzinga Pro. The Board of Directors appointed Richard (Rick) Barry as Executive Chairman and the company’s principal executive officer, effective immediately. The company is searching for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company’s Chairman, President, and CEO, who resigned and will remain employed by the Company until September 13, 2024, in
